TWEAK Human；TWEAK/TNFRSF12

TWEAK, short for TNF-related weak inducer of apoptosis, is also known as TNFSF12 and DR3LG. It is a type II transmembrane protein belonging to the TNF superfamily. It is expressed widely in many tissues, such as the heart, skeletal muscle, spleen and peripheral blood. Binding of TWEAK to its receptor TWEAKR induces NF-κB activation, chemokine secretion and apoptosis in certain cell types. TWEAK has also been reported to promote endothelial cell proliferation and migration, thus serving as a regulator of angiogenesis.

Alisa:TNF-related weak inducer of apoptosis, TNFSF12, DR3LG, Apo3-Ligand

Character description:
Species：……………………………Human
Source：……………………………CHO
Measured Molecular Weight：……20-22 kDa, observed by reducing SDS-PAGE.
Purity：………………………………> 95% as analyzed by SDS-PAGE and HPLC.
Formulation：………………………Lyophilized after extensive dialysis against PBS.
Reconstitution：……………………Reconstituted in ddH2O or PBS at 100 μg/ml.
Endotoxin Level：…………………< 0.2 EU/μg, determined by LAL method.


Sequence：

RKTRARRAIA AHYEVHPRPG QDGAQAGVDG TVSGWEEARI
NSSSPLRYNR QIGEFIVTRA GLYYLYCQVH FDEGKAVYLK
LDLLVDGVLA LRCLEEFSAT AASSLGPQLR LCQVSGLLAL
RPGSSLRIRT LPWAHLKAAP FLTYFGLFQV H

Storage：
Lyophilized recombinant Human TWEAK remains stable up to 6 months at lower than -70°C from date of receipt. Upon reconstitution, Human TWEAK should be stable up to 1 week at 4°C or up to 2 months at -20°C.

Transport condition：2~8℃ 

Biological activity：
ED50 < 1 ng/ml, measured in a cell cytotoxicity assay using HTB-38 (HT-29) cells.